<DOC>
	<DOC>NCT00581620</DOC>
	<brief_summary>To determine immunogenicity of the heptavalent CRM197 pneumococcal conjugate in children with immunodeficiency condition. To evaluate tolerability of PrevenarÂ® in that population.</brief_summary>
	<brief_title>Study Evaluating Prevenar Immunogenicity in High Risk Children</brief_title>
	<detailed_description>This study will require 24 months to be completed. Each child will participate for a period of time according to age of the 1st dose of vaccination: infants up to 6 months of age will be evaluated for 5 months; infants between 7 to 11 months will be evaluated for 3 months; children between 12 months up to 9 years of age will be evaluate for 2 months</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Children between 2 months to 9 years old. Children with HIV+; Sickle Cell disease; Neprotic symdrome; Chronic pulmonary disease No history of seizures</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>9 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>pneumococcus conjugated vaccine</keyword>
</DOC>